Company / Cost of Revenue
Viatris Cost of Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$9.3B
FY2025
5-year range
$7.6B / $9.3B
FY2021-FY2025
Trend
+1.9%
vs FY2024
Sector context
#8 of 85
Health Care
What the data says
Among 85 Health Care companies, Viatris is in the bottom 9% for cost of revenue. Cost of Revenue has increased for 5 consecutive years, from $7.4B in FY2020 to $9.3B in FY2025.
Based on SEC 10-K filings.
$9.3B in FY2025 with a 5-year CAGR of +4.6%. Top quartile in the Health Care sector.
Increased from $9.0B to $9.3B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +4.5%
- 5-Year CAGR
- +4.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 85This company $9.3B Sector average $2.0B
▼
+368.3% above sector average
Key checks
Key Insights
- Viatris's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +4.6%, indicating consistent growth.
- In FY2025, cost of revenue increased 1.9% year-over-year.
- Ranks #8 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.3B | +1.9% |
| FY2024 | $9.1B | +1.4% |
| FY2023 | $9.0B | +10.3% |
| FY2022 | $8.1B | +7.2% |
| FY2021 | $7.6B | +2.3% |
| FY2020 | $7.4B | -2.2% |
| FY2019 | $7.6B | +2.3% |
| FY2018 | $7.4B | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026